<DOC>
	<DOCNO>NCT02458560</DOCNO>
	<brief_summary>The purpose study assess safety device success Edwards CENTERA Transcatheter Heart Valve ( THV ) System symptomatic adult patient severe aortic stenosis .</brief_summary>
	<brief_title>Safety Performance Study Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve</brief_title>
	<detailed_description>This non-randomized , prospective , multi-center safety device success study . Up two hundred ( 200 ) patient plan implanted 35 participate investigational center Europe , Australia New Zealand . Patient participation last minimum 5 year . Patients assess follow interval : baseline , discharge , 30 day , 6 month , 1 year annually thereafter 5 year .</detailed_description>
	<criteria>1 . Heart team ( include cardiac surgeon ) agree eligibility include assessment TAVI appropriate . 2 . High surgical risk : 8 ≤ STS Score ≤ 15 15 ≤ Logistic EuroSCORE I ≤ 40 . 3 . NYHA ≥ II . 4 . Study patient adult legal consent age . 5 . Study patient provide write informed consent comply study procedure followup visit . 1 . Acute myocardial infarction ≤ 30 day intend treatment . 2 . Untreated clinically significant coronary artery disease require revascularization . 3 . Aortic valve congenital unicuspid congenital bicuspid valve . 4 . Mixed aortic valve disease ( predominant aortic regurgitation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Transcatheter Aortic Valve Replacement</keyword>
	<keyword>Aortic Stenosis</keyword>
</DOC>